This text is a result of machine translation.
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Research
Healthcare, Technology, Consumer DiscretionaryLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
R&D of Anti-COVID-19 Drugs is Blooming in China
Anti-epidemic stocks moved higher in early trading of the Hong Kong Stock Exchange today, with Kintor Pharma-B (Chinese: 开拓药业,09939:HK) and Shandong Xinhua Pharmaceutical (Chinese: 新华制药,00719:HK) leading the rally on the back of thriving R&D of anti-coronavirus drugs.
May 17, 2022 02:15 PM
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Upside foods, a cell meat enterprise, received US $400 million in financing, the highest single transaction in the industry
TG ImmunoPharma Raises Hundreds of Mns of CNY in Pre-Series A Financing Round
TG ImmunoPharma, specializing in NK (Natural Killer) cell-based checkpoint immunotherapy drugs, is uncovering the linchpin of the next-generation method of treating cancer with the fresh funding.
May 12, 2022 06:46 PM
Lingfu biology, an experimental animal research service provider, completed a pre-A round of financing of more than 200 million yuan
Hefei Tiangang immunopharmaceutical Co., Ltd., a tumor immunotherapy enterprise, completed a round of pre-A financing of hundreds of millions of yuan
Ping An Health's 2021 annual report was released, with a revenue of 7.3 billion yuan, a year-on-year increase of 8%
Yiyao technology won ten million yuan of angel + round financing to promote the research pipeline in the field of life extension and metabolic diseases
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
May 12, 2022 05:41 PM